Philips announced the launch of its IntraSight Plus interventional cardiology platform, a comprehensive system that integrates IVUS imaging, iFR/FFR physiology, and co‑registration to support minimally invasive coronary procedures. The platform received FDA 510(k) clearance and CE marking, enabling marketing in the United States and European markets. The first patient case was performed on March 19, 2026, in Germany.
Philips claims the platform can reduce system operation time by up to 47%, improving workflow efficiency for cardiac specialists. The integration of diagnostic and treatment planning tools supports Philips’ connected care strategy, which has been a focus since the COVID‑19 pandemic and is reinforced by recent acquisitions such as BioTelemetry and Capsule Technologies.
The launch follows Philips’ Q4 2025 earnings, which reported 7% comparable sales growth and a 15.1% adjusted EBITA margin, underscoring the company’s ability to drive profitability while investing in innovation. CEO Roy Jakobs highlighted the company’s “strong order growth and sales, robust margin expansion despite tariffs, and solid cash generation” as evidence of resilient performance.
In the competitive interventional cardiology market, Philips faces rivals such as Boston Scientific, which also offers FFR guidewires and other device solutions. By bundling imaging and physiology into a single platform, Philips aims to differentiate itself and capture a larger share of cath‑lab workflows, potentially accelerating adoption and revenue growth.
The IntraSight Plus launch signals Philips’ continued commitment to integrated health technology solutions and positions the company to capitalize on the growing demand for minimally invasive cardiac procedures driven by an aging population and rising cardiovascular disease prevalence.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.